23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Madrigal Pharmaceuticals, Inc. › 2025-2026

Madrigal Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Madrigal Pharmaceuticals, Inc.’s Form 8-K, filed June 17, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Reported items
  • 407Asset managers, any item
  • 3,242Fund votes
  • June 17, 2026Meeting date

Results at a glance

Meeting of June 17, 2026: 7 items on Madrigal Pharmaceuticals, Inc.’s Form 8-K, filed June 17, 2026: 3 elected · 4 approved.

Dissent

Notable dissent: 1 director (11.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Madrigal Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Madrigal Pharmaceuticals, Inc.

These tallies are Madrigal Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Madrigal Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 17, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Julian C. Baker 17,363,250---- 2,227,7341,731,844 89%Elected—
Elect Director: Daniel J. Brennan 19,469,200---- 121,7841,731,844 99.4%Elected—
Elect Director: James M. Daly 18,921,185---- 669,7991,731,844 97%Elected—
2. On a non-binding, advisory basis, the compensation of the Company's named executive officers 19,000,895561,05829,031 --1,731,844 97%Approved—
3. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 21,256,31537,50529,009 ---- 99.8%Approved—
4. The 2026 Stock Plan 19,118,851446,39425,739 --1,731,844 98%Approved—
5. The 2026 ESPP 19,546,76622,94821,270 --1,731,844 99.9%Approved—

This meeting is also recorded here as June 16, 2026; both records come from the same filing, so the date should be checked against it.

Source: Madrigal Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 17, 2026 — read the filing on EDGAR.

How asset managers voted at the Madrigal Pharmaceuticals, Inc. 2025-2026 meeting

407 asset managers disclosed a vote on at least one Madrigal Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Madrigal Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Daniel J. Brennan

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 19,469,200WITHHELD: 121,784
Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Re-election of Class I directors: Daniel Brennan

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Daniel J. Brennan”): 19,469,200 for, 121,784 withheld, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 104 asset managers voting on “Re-election of Class I directors: Daniel Brennan” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,235,3420 01,018For
JANUS INVESTMENT FUND1,109,7770 00For
Fidelity665,4490 00For
BlackRock417,9290 00For
T. Rowe Price224,8670 00For
Charles Schwab217,7590 00For
Lord Abbett206,6380 00For
Invesco192,7560 00For
State Street162,3020 00For
American Century115,4170 00For
Columbia Threadneedle99,6050 00For
Manager Directed Portfolios97,2640 00For
Jackson National84,5110 00For
WILLIAM BLAIR FUNDS65,1280 00For
Equitable63,1330 00For
Goldman Sachs58,0040 00For
TIAA57,7880 00For
AIG/SunAmerica43,3810 00For
HARBOR FUNDS43,3010 00For
ACAP Strategic Fund39,6090 00For
Brighthouse39,4840 00For
Voya38,6760 00For
BNY Mellon38,5570 00For
Putnam37,7760 00For
JANUS ASPEN SERIES36,7440 00For

Fund voting reports, all 104 managers: 7,012,258 for, 21,026 withheld, 22 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “Re-election of Class I directors: Daniel Brennan” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH130,2100 00For
MARCO INVESTMENT MANAGEMENT LLC40 00For
Keel Point, LLC20 00For

Institutional-manager reports, all 3 managers: 130,216 for.

Elect Director: James M. Daly

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 18,921,185WITHHELD: 669,799
Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Re-election of Class I directors: James Daly

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: James M. Daly”): 18,921,185 for, 669,799 withheld, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 104 asset managers voting on “Re-election of Class I directors: James Daly” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,236,3590 10For
JANUS INVESTMENT FUND1,109,7770 00For
Fidelity665,4490 00For
BlackRock417,9290 00For
T. Rowe Price00 0224,867Withhold
Charles Schwab217,7590 00For
Lord Abbett206,6380 00For
Invesco192,7560 00For
State Street162,3020 00For
American Century115,4170 00For
Columbia Threadneedle99,6050 00For
Manager Directed Portfolios97,2640 00For
Jackson National84,5110 00For
WILLIAM BLAIR FUNDS65,1280 00For
Equitable39,7390 023,394Mixed
Goldman Sachs58,0040 00For
TIAA57,7880 00For
AIG/SunAmerica43,3810 00For
HARBOR FUNDS43,3010 00For
ACAP Strategic Fund39,6090 00For
Brighthouse30,2440 09,240Mixed
Voya38,6760 00For
BNY Mellon38,5570 00For
Putnam37,7760 00For
JANUS ASPEN SERIES36,7440 00For

Fund voting reports, all 104 managers: 6,677,086 for, 356,197 withheld, 1 abstained, 22 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “Re-election of Class I directors: James Daly” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH130,2100 00For
MARCO INVESTMENT MANAGEMENT LLC40 00For
Keel Point, LLC20 00For

Institutional-manager reports, all 3 managers: 130,216 for.

Elect Director: Julian C. Baker

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 17,363,250WITHHELD: 2,227,734

Prior year: 90.5% for (June 20, 2025 meeting) ▼ 1.8 pts

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Re-election of Class I directors: Julian Baker

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Julian C. Baker”): 17,363,250 for, 2,227,734 withheld, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 104 asset managers voting on “Re-election of Class I directors: Julian Baker” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,740,7280 5495,627Mixed
JANUS INVESTMENT FUND1,109,7770 00For
Fidelity665,4490 00For
BlackRock417,9290 00For
T. Rowe Price00 0224,867Withhold
Charles Schwab217,7590 00For
Lord Abbett206,6380 00For
Invesco192,7560 00For
State Street1,2820 0161,020Withhold
American Century115,4170 00For
Columbia Threadneedle99,6050 00For
Manager Directed Portfolios97,2640 00For
Jackson National84,5110 00For
WILLIAM BLAIR FUNDS65,1280 00For
Equitable39,7390 023,394Mixed
Goldman Sachs57,0220 0982For
TIAA57,7880 00For
AIG/SunAmerica43,3810 00For
HARBOR FUNDS43,3010 00For
ACAP Strategic Fund39,6090 00For
Brighthouse30,2440 09,240Mixed
Voya38,6760 00For
BNY Mellon38,5570 00For
Putnam37,7760 00For
JANUS ASPEN SERIES36,7440 00For

Fund voting reports, all 104 managers: 5,946,086 for, 1,087,193 withheld, 5 abstained, 22 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “Re-election of Class I directors: Julian Baker” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH130,2100 00For
MARCO INVESTMENT MANAGEMENT LLC40 00For
Keel Point, LLC20 00For

Institutional-manager reports, all 3 managers: 130,216 for.

Approval of Madrigal Pharmaceuticals, Inc. 2026 employee stock purchase plan

No official matchCOMPENSATION

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 104 asset managers

Description as filed by funds: APPROVAL OF MADRIGAL PHARMACEUTICALS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN

The 104 asset managers below reported 7,003,016 for, 3,508 against, 22 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,003,016AGAINST: 3,508NOT VOTED: 22
Largest asset managers voting on “APPROVAL OF MADRIGAL PHARMACEUTICALS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,236,3600 00For
JANUS INVESTMENT FUND1,109,7770 00For
Fidelity665,4490 00For
BlackRock417,9290 00For
T. Rowe Price224,8670 00For
Charles Schwab217,7590 00For
Lord Abbett206,6380 00For
Invesco192,7560 00For
State Street162,3020 00For
American Century115,4170 00For
Columbia Threadneedle99,6050 00For
Manager Directed Portfolios97,2640 00For
Jackson National84,5110 00For
WILLIAM BLAIR FUNDS65,1280 00For
Equitable63,1330 00For
Goldman Sachs58,0040 00For
TIAA57,7880 00For
AIG/SunAmerica43,3810 00For
HARBOR FUNDS43,3010 00For
ACAP Strategic Fund39,6090 00For
Voya38,6760 00For
BNY Mellon38,5570 00For
Putnam37,7760 00For
JANUS ASPEN SERIES36,7440 00For
AllianceBernstein33,1560 00For

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

Approval of Madrigal Pharmaceuticals, Inc. 2026 stock plan

No official matchCOMPENSATION

99.2% of fund votes cast · no official result

FOR
Details: description as filed, votes by 104 asset managers

Description as filed by funds: APPROVAL OF MADRIGAL PHARMACEUTICALS, INC. 2026 STOCK PLAN

The 104 asset managers below reported 6,951,085 for, 55,439 against, 22 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 6,951,085AGAINST: 55,439NOT VOTED: 22
Largest asset managers voting on “APPROVAL OF MADRIGAL PHARMACEUTICALS, INC. 2026 STOCK PLAN” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,236,3591 00For
JANUS INVESTMENT FUND1,109,7770 00For
Fidelity665,4490 00For
BlackRock417,9290 00For
T. Rowe Price224,8670 00For
Charles Schwab217,7590 00For
Lord Abbett206,6380 00For
Invesco192,7560 00For
State Street162,2975 00For
American Century115,4170 00For
Columbia Threadneedle99,6050 00For
Manager Directed Portfolios97,2640 00For
Jackson National84,5110 00For
WILLIAM BLAIR FUNDS65,1280 00For
Equitable63,1330 00For
Goldman Sachs58,0040 00For
TIAA57,7880 00For
AIG/SunAmerica43,3810 00For
HARBOR FUNDS43,3010 00For
ACAP Strategic Fund39,6090 00For
Voya38,6760 00For
BNY Mellon38,5570 00For
Putnam037,776 00Against
JANUS ASPEN SERIES36,7440 00For
AllianceBernstein33,1560 00For

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

On a non-binding, advisory basis, the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 19,000,895AGAINST: 561,058

Prior year: 98.9% for (June 20, 2025 meeting) ▼ 1.8 pts

Details: description as filed, official tally, votes by 406 asset managers

Description as filed by funds: ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“2. On a non-binding, advisory basis, the compensation of the Company's named executive officers”): 19,000,895 for, 561,058 against — passed, per its Form 8-K filed June 17, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 105 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,236,3591 00For
JANUS INVESTMENT FUND1,109,7770 00For
Fidelity661,0614,388 00For
BlackRock372,95344,976 00Mixed
T. Rowe Price224,8670 00For
Charles Schwab217,7590 00For
Lord Abbett206,6380 00For
Invesco192,7560 00For
State Street162,23963 00For
American Century115,4170 00For
Columbia Threadneedle99,6050 00For
Manager Directed Portfolios97,2640 00For
Jackson National84,5110 00For
WILLIAM BLAIR FUNDS65,1280 00For
Equitable63,1330 00For
Goldman Sachs58,0040 00For
TIAA57,7880 00For
AIG/SunAmerica43,3810 00For
HARBOR FUNDS43,3010 00For
ACAP Strategic Fund39,6090 00For
Brighthouse39,4840 00For
Voya38,6760 00For
BNY Mellon38,5570 00For
Putnam37,7760 00For
JANUS ASPEN SERIES36,7440 00For

Fund voting reports, all 105 managers: 6,971,207 for, 58,570 against, 3,508 abstained, 22 not voted, 40 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 330 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson3,280,8100 00For
BAKER BROS. ADVISORS LP2,141,7010 00For
RTW INVESTMENTS, LP1,993,6870 00For
Wellington663,1830 00For
BlackRock576,59266,347 00Mixed
PAULSON & CO. INC.593,8250 00For
Polar Capital Holdings Plc547,2840 00For
State Street515,589251 00For
Fidelity466,6640 00For
GEODE CAPITAL MANAGEMENT, LLC458,2030 00For
Avoro Capital Advisors LLC400,0770 00For
T. Rowe Price341,332500 00For
Invesco302,5660 00For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC288,7090 00For
LORD, ABBETT & CO. LLC234,0670 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.219,8090 00For
Charles Schwab218,4900 00For
PICTET ASSET MANAGEMENT SA173,1380 00For
Rock Springs Capital Management LP170,9990 00For
Vanguard155,1610 00For
Hood River Capital Management LLC152,7820 00For
Northern Trust136,7241,237 00For
American Century132,6960 00For
Artisan132,5790 00For
Erste Asset Management GmbH130,2100 00For

Institutional-manager reports, all 330 managers: 16,361,233 for, 279,527 against, 3,366 abstained, 363 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the…

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 21,256,315AGAINST: 37,505

Prior year: 99.1% for (June 20, 2025 meeting) ▲ 0.7 pts

Details: description as filed, official tally, votes by 109 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“3. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 21,256,315 for, 37,505 against — passed, per its Form 8-K filed June 17, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 105 asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,236,3600 00For
JANUS INVESTMENT FUND1,109,7770 00For
Fidelity665,4490 00For
BlackRock417,9290 00For
T. Rowe Price224,8670 00For
Charles Schwab217,7590 00For
Lord Abbett206,6380 00For
Invesco192,7560 00For
State Street162,2975 00For
American Century115,4170 00For
Columbia Threadneedle99,6050 00For
Manager Directed Portfolios97,2640 00For
Jackson National84,5110 00For
WILLIAM BLAIR FUNDS65,1280 00For
Equitable63,1330 00For
Goldman Sachs58,0040 00For
TIAA57,7880 00For
AIG/SunAmerica43,3810 00For
HARBOR FUNDS43,3010 00For
ACAP Strategic Fund39,6090 00For
Brighthouse39,4840 00For
Voya38,6760 00For
BNY Mellon38,5570 00For
Putnam37,7760 00For
JANUS ASPEN SERIES36,7440 00For

Fund voting reports, all 105 managers: 7,030,271 for, 5 against, 3,508 abstained, 22 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 4 asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH130,2100 00For
McGowan Group Asset Management, Inc.5000 00For
MARCO INVESTMENT MANAGEMENT LLC40 00For
Keel Point, LLC20 00For

Institutional-manager reports, all 4 managers: 130,716 for.

Largest Madrigal Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 23,041,918 shares outstanding at the time of that meeting.

Fund voting reports: top Madrigal Pharmaceuticals, Inc. shareholders by shares voted on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 9.71%
2JANUS INVESTMENT FUND 4.82%
3Fidelity 2.89%
4BlackRock 1.81%
5T. Rowe Price 0.98%
6Charles Schwab 0.95%
7Lord Abbett 0.90%
8Invesco 0.84%
9State Street 0.70%
10American Century 0.50%
Institutional-manager reports: top Madrigal Pharmaceuticals, Inc. shareholders by shares voted on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 14.24%
2BAKER BROS. ADVISORS LP 9.29%
3RTW INVESTMENTS, LP 8.65%
4Wellington 2.88%
5BlackRock 2.79%
6PAULSON & CO. INC. 2.58%
7Polar Capital Holdings Plc 2.38%
8State Street 2.24%
9Fidelity 2.03%
10GEODE CAPITAL MANAGEMENT, LLC 1.99%

Reported Madrigal Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Madrigal Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Avoro Capital Advisors LLC2,319,666 10.07%Proxy statement (DEF 14A), table as of April 1, 2026
Baker Bros. Advisors LP and affiliates2,319,666 10.07%Proxy statement (DEF 14A), table as of April 1, 2026
Julian Baker2,319,666 10.07%Proxy statement (DEF 14A), table as of April 1, 2026
JANUS HENDERSON GROUP PLC2,018,647 8.76%Schedule 13G, filed May 15, 2026
RTW Investments, LP and affiliates1,993,687 8.65%Proxy statement (DEF 14A), table as of April 1, 2026
Vanguard Group1,808,894 7.85%Form 13F, quarter ended March 31, 2026
Paul Friedman, M.D.1,779,710 7.72%Proxy statement (DEF 14A), table as of April 1, 2026
Rebecca Taub, M.D.1,779,710 7.72%Proxy statement (DEF 14A), table as of April 1, 2026
Paulson & Co. Inc. and affiliates1,707,522 7.41%Proxy statement (DEF 14A), table as of April 1, 2026
BlackRock1,559,965 6.77%Form 13F, quarter ended March 31, 2026

Percentages above are of 23,041,918 shares outstanding, as reported by Madrigal Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Madrigal Pharmaceuticals, Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 407 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 3,242 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION — Madrigal Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Madrigal Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Madrigal Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Madrigal Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Madrigal Pharmaceuticals (MDGL) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/madrigal-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.